Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
This research aims to compare two approaches for treating previously untreated amblyopia in children aged 3 to under 13 years. It evaluates whether using glasses and patching at the same time leads to similar improvements in vision as first using glasses alone, followed by patching only if needed. The trial focuses on children with amblyopia caused by differences in eye alignment or prescription errors. Children will be assigned randomly to one of two treatment groups one group will wear glasses full-time and add patching for 2 hours daily only if there is no improvement after glasses alone the other group will wear glasses and patch the weaker eye for 2 hours daily at the same time from the start. Vision tests will be done at baseline and follow-up visits every 8 weeks for up to 56 weeks. Participants will have their distance visual acuity measured with trial frames before and after getting their glasses to confirm eligibility. During the study, vision will be monitored to classify improvement or stability, guiding whether patching is needed in the sequential group. Outcomes include changes in vision clarity after 56 weeks and quality-of-life assessments. Regular visits help track progress and safety until study completion.
Actively Recruiting
This research is evaluating dichoptic treatments for children aged 8 to 12 years with amblyopia, a vision condition. Participants will be randomly assigned to one of three groups wearing the Luminopia headset to watch dichoptic movies, using the Vivid Vision headset to play dichoptic games, or continuing with optical correction alone if needed. The study aims to compare these approaches to improve visual acuity in the amblyopic eye. Participants assigned to the Luminopia group will watch dichoptic movies or shows for one hour daily, six days per week, while using their prescribed optical correction if needed. The Vivid Vision group will play dichoptic games using a virtual reality headset for approximately 25 minutes daily, six days per week, also with optical correction if required. The third group will continue full-time optical correction alone. At 18 weeks, those initially on optical correction alone who show significant vision difference may be offered a chance to try either dichoptic treatment, with follow-up visits extending to 36 weeks. Throughout the study, participants will have clinical assessments at 9 and 18 weeks after starting treatment. Those switching to dichoptic therapy after 18 weeks will have additional visits at 27 and 36 weeks. Researchers will measure changes in visual acuity of the amblyopic eye and assess quality of life through questionnaires. The study includes monitoring adherence to treatments and continues for up to 36 weeks for some participants, with safety and effectiveness evaluated during follow-up visits.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are studying a new medicine called PF-08634404 to see how well it works in adults with metastatic colorectal cancer, which is cancer that has spread to other parts of the body. The study compares PF-08634404 combined with approved chemotherapy to an approved medicine called Bevacizumab combined with chemotherapy. The goal is to understand if the new medicine can improve outcomes for people whose cancer has spread or returned after previous treatments. Participants are randomly assigned to one of two treatment groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. All medicines are given through intravenous IV infusions at a clinical site. Treatment is given in cycles, and participants may continue treatment as long as it is helping and side effects are manageable. After treatment ends, participants return for a final visit around 30 to 37 days later. During the study, participants have regular visits for treatment, health checks, and tests. Follow-up continues every 12 weeks through phone, in-person visits, or health record reviews to monitor health status and any new treatments. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, side effects, quality of life, and drug levels. The study is expected to last about 33 months per participant.